SAN DIEGO, Oct. 23, 2017 /PRNewswire/ -- NuVasive, Inc.
(NASDAQ: NUVA), the leader in spine technology innovation, focused
on transforming spine surgery with minimally disruptive,
procedurally-integrated solutions, today announced new lateral
solutions that enable surgeons to perform lateral single-position
surgery and expand the Company's comprehensive lateral
portfolio.
Nearly 15 years ago, NuVasive revolutionized spine surgery
through the development of XLIF®, the only lateral approach spine
procedure proven with extensive clinical evidence and more than 400
peer-reviewed, XLIF-specific publications. NuVasive continues to
innovate the XLIF procedure today by introducing lateral
single-position approach to surgery and thereby increasing O.R.
efficiency by reducing the number of times a patient has to be
repositioned, expanding the benefits of lateral surgery to more
spinal levels and decreasing the amount of time a patient is under
anesthesia.
"NuVasive earned its reputation as the disruptive leader in
spine when we created the lateral market 15 years ago, and we've
remained relentlessly focused on advancing and expanding our
technology to transform patients' lives, surgical practices and
hospitals' ability to provide superior, best-in-care patient
results," said Gregory T. Lucier,
chairman and chief executive officer of NuVasive. "We are
transforming spine surgery around the globe through our unique
technology including lateral single position surgery, the most
advanced interbody implants with advanced materials science,
including porous PEEK and 3D-printed porous titanium, and
integrated O.R. systems that support spinal alignment, radiation
reduction and imaging."
Lateral Procedural Solutions
NuVasive expands its
lateral procedural solutions with Lateral ALIF, XLIF Crestline and
Lateral MAS Fixation, enabling surgeons to treat pathologies from
T6-S1 to deliver efficient, predictable clinical outcomes.
- The Lateral ALIF procedure is built on a new retractor
system designed to provide direct access to L5-S1 with the patient
in a lateral decubitus position. With the characteristics of a
traditional supine ALIF, Lateral ALIF enables the surgeon to
perform lateral single-position surgery, saving time and improving
efficiency in the OR.
- Built on the XLIF platform, XLIF Crestline is a
supplemental solution, designed to gain lateral access to
challenging L4-L5 levels where an XLIF cannot be performed, such as
high crest, anterior psoas or an anterior plexus. The off-angle
procedure allows access to disc space traditionally reached through
a posterior approach, and uses the Company's leading technologies
including NVM5®, MaXcess® and XLIF implants.
- Lateral MAS Fixation is an adapted technique using
Reline®, the Company's best-in-class fixation system designed to
preserve and restore spinal alignment. The surgical technique
provides surgeon partners reproducible results and increased O.R.
efficiency when utilized with the Company's leading lateral
procedural solutions portfolio.
"NuVasive continues to take ownership of the lateral surgery,
making it better for us as surgeons and making it better for our
patients," said Dr. Brian Kwon,
orthopedic surgeon at New England Baptist
Hospital. "Using XLIF, XLIF Crestline and Lateral ALIF
provides the advantage of maintaining your patient in a single
position. If you look, most of lumbar fusion surgery has really
been done at L4 to S1, and so the ability to have these procedures
available is tremendous."
Advanced Materials Science Portfolio
Paving the way in
spine surface technology, the Company unveiled its Advanced
Materials Science (AMS) portfolio designed to deliver enhanced
osseointegration and biomechanics through innovative implant
design. With leading advanced materials in surface, structure and
imaging characteristics, the portfolio includes the Company's
recently launched Modulus™ XLIF, a 3D-printed porous titanium
implant, and porous PEEK™ (polyetheretherketone) technology after
last month's acquisition of Vertera Spine. NuVasive is the only
medical device company to offer porous interbody technology across
both PEEK and titanium materials, thereby addressing the spectrum
of surgeons' needs and preferences for advanced interbody implants.
The Company's future plans include integrating the porous PEEK
technology across all its procedural offerings
The expanded lateral solutions and AMS portfolio demonstrate the
Company's deep commitment to bold innovation. These advancements in
spine care join NuVasive other breakthroughs like Integrated Global
Alignment® (iGA), a platform of procedurally based technologies
designed to enhance clinical and economic outcomes by increasing
the predictability of achieving global spinal alignment, advanced
neuromonitoring with the NVM5 system, and radiation reduction with
LessRay®.
NuVasive 2017 NASS Annual Meeting Participation
Details
NuVasive will showcase its market-leading,
procedurally-integrated technologies, including the new Lateral
ALIF, Modulus XLIF and LessRay in NuVasive Booth #713 at the
NASS Annual Meeting held October 25-28,
2017 in Orlando, Fla.
The Company also will host a surgical innovation lab
demonstration presented by Robert
Isaacs, MD, Mark Medley, MD,
William D. Smith, MD, and
J. Alex Thomas, MD, titled "Single
Position Lateral Solutions to Treat L4-S1, Featuring Advanced
3D-Printed Implants and LessRay Radiation Emission Reduction
Technology" on October 26, 2017 from
8:00 a.m. to 10:00 a.m. in the Green
Lab at the Orange County
Convention Center.
Visit here for more details and a schedule of
events.
About NuVasive
NuVasive,
Inc. (NASDAQ: NUVA) is the leader in spine technology innovation,
focused on transforming spine surgery and beyond with minimally
invasive, procedurally-integrated solutions designed to deliver
reproducible and clinically-proven surgical outcomes. The Company's
portfolio includes access instruments, implantable hardware,
biologics, software systems for surgical planning, navigation and
imaging solutions, magnetically adjustable implant systems for
spine and orthopedics, and intraoperative monitoring service
offerings. With $962 million in
revenues (2016), NuVasive has an approximate 2,300 person workforce
in more than 40 countries serving surgeons, hospitals and patients.
For more information, please visit www.nuvasive.com.
Forward-Looking Statements
NuVasive cautions
you that statements included in this news release that are not a
description of historical facts are forward-looking statements that
involve risks, uncertainties, assumptions and other factors which,
if they do not materialize or prove correct, could cause NuVasive's
results to differ materially from historical results or those
expressed or implied by such forward-looking statements. The
potential risks and uncertainties which contribute to the uncertain
nature of these statements include, among others, risks associated
with acceptance of the Company's surgical products and procedures
by spine surgeons, development and acceptance of new products or
product enhancements, clinical and statistical verification of the
benefits achieved via the use of NuVasive's products (including the
iGA platform), the Company's ability to effectually manage
inventory as it continues to release new products, its ability to
recruit and retain management and key personnel, and the other
risks and uncertainties described in NuVasive's news releases and
periodic filings with the Securities and Exchange Commission.
NuVasive's public filings with the Securities and Exchange
Commission are available at www.sec.gov. NuVasive assumes no
obligation to update any forward-looking statement to reflect
events or circumstances arising after the date on which it was
made.
View original content with
multimedia:http://www.prnewswire.com/news-releases/nuvasive-extends-its-leadership-as-lateral-spine-technology-innovator-with-new-lateral-single-position-surgery-procedure-300540978.html
SOURCE NuVasive, Inc.